Baricitinib, an oral selective JAK1/JAK2 inhibitor, improved the clinical signs and symptoms of moderate-to-severe AD in phase 3 studies and was effective and safe in the long term [130,131,132,133]. Here, JAK1 is linked to Alzheimer disease.